10 Sep 2018 07:00
Issued: 7 September 2018, London UK - LSE Announcement
GSK receives complete response letter from US FDA for use of mepolizumab in COPD patients
GlaxoSmithKline plc (LSE/NYSE: GSK) today received a complete response letter (CRL) from the US FDA regarding its application for mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD), guided by blood eosinophil counts.
The CRL states that more clinical data are required to support an approval. GSK will work closely with the FDA to determine the appropriate next steps for the supplementary biologics licence application (sBLA).
About mepolizumab
First approved in 2015 for severe eosinophilic asthma, and also licenced for EGPA in the US, mepolizumab is the first-in-class monoclonal antibody that targets IL-5. It is believed to work by preventing IL-5 from binding to its receptor on the surface of eosinophils. Inhibiting IL-5 binding in this way reduces blood eosinophils.
Mepolizumab has been studied in over 3000 patients in 16 clinical trials across a number of eosinophilic indications and is currently being investigated for severe hypereosinophilic syndrome and nasal polyposis, in addition to the sBLA filed for the treatment of patients with COPD.
GSK in respiratory disease
GSK has led the way in developing innovative medicines to advance the management of asthma and COPD for nearly 50 years. Over the last five years we have launched six innovative medicines responding to continued unmet patient need, despite existing therapies. This is an industry-leading portfolio in breadth, depth and innovation, developed to reach the right patients, with the right treatment.
GSK - a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
Trademarks are owned by or licensed to the GSK group of companies.
GSK enquiries: |
|
|
|
UK Media enquiries: | Simon Steel | +44 (0) 20 8047 5502 | (London) |
|
|
|
|
US Media enquiries: | Karen Hagens | +1 919 483 2863 | (North Carolina) |
| Anna Padula | +1 215 760 2928 | (Philadelphia) |
|
|
|
|
Analyst/Investor enquiries: | Sarah Elton-Farr | +44 (0) 20 8047 5194 | (London) |
| James Dodwell | +44 (0) 20 8047 2406 | (London) |
| Danielle Smith | +44 (0) 20 8047 7562 | (London) |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
|
|
|
|
Cautionary statement regarding forward-looking statementsGSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D Principal risks and uncertainties in the company's Annual Report on Form 20-F for 2017.
|
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
Glaxosmithkline (GSK)